13. Mikityuk M.R., Hizhnyak O.O., Sulima T.N. Sravnitel'naya ocenka nekotoryh pokazatelej uglevodnogo obmena u bol'nyh s gormonal'noaktivnymi adenomami gipofiza [Comparative evaluation of some indicators of carbohydrate metabolism in patients with hormonal pituitary adenomas]// Saharnyj diabet. 2014;(1):70–74.

14. Trigolosova I.V. , Dreval' A.V. Epidemiologiya i patogenez narushenij uglevodnogo obmena pri akromegalii (obzor literatury) [Epidemiology and pathogenesis of disorders of carbohydrate metabolism in acromegaly]// Regulyarnye vypuski «RMZh» №8 ot 06.05.2015 str. 436.

15. Hizhnyak O. O., Gogitidze T. G. Osobennosti uglevodnogo obmena u bol'nyh s prolaktinomami na etapah supressivnoj terapii agonistami dofamina [Features of carbohydrate metabolism in patients with prolactinomas at the stages of suppressive therapy with dopamine agonists] // Problemi endokrinnoї patologiї № 3, 2015. - S. 67-75.

1. Sharma S. T., Nieman L. K., Feelders R. A.. Comorbidities in Cushing’s disease // Pituitary. 2015; 18(2): 188–194.

2. Hannon A. M., Thompson C. J., Sherlock M. Diabetes in Patients with Acromegaly //Current Diabetes Reports. 2017. Vol. 17.. 2. P. 8

3. Sebko T.V., Hejdar L.A., Koneeva S.S. Giperprolaktinemiya // Medical Journal of the Russian Federation, Russian Journal. 2016; 22 (5)/ - C/ 250-260. DOI 10.18821/0869-2106-2016-22-5-250-259.

4. Boockenooghe T., Sisino G., Aurientis S., Chinetti-Gbaguidi G., Kerr-Conte J., Staels B. et al. Adipose tissue macrophages(ATM)of obese patients are releasing cucreased levels of prolactin during an infl ammatory challenge: A role for prolactin in diabesity? Biochim. Biophys. Acta. 2014; 1842(4): 584—93.

5. Baldelli R. et al. Glucose homeostasis in acromegaly: effects of long‐acting somatostatin analogues treatment //Clinical endocrinology. – 2003. – Vol. 59. – №. 4. – P. 492-499.

6. Dreval' A.V., Trigolosova I.V., Vinogradova A.V. Mekhanizmy narushenij uglevodnogo obmena pri akromegalii v zavisimosti ot lecheniya [The mechanisms of disorders of carbohydrate metabolism in acromegaly, depending on the treatment] // Problemy endokrinologii - №1.2015. - tom 61. - str.23-29.

7. Urbani C, Sardella C, Calevro A, et al. Effects of medical therapies for acromegaly on giucose metabolism. European journal of endocrinology/ European Federation of Endocrine Societies. 2013;169 (1):99-108.

8. Hannon A. M., Thompson C. J., Sherlock M. Diabetes in Patients with Acromegaly //Current Diabetes Reports. 2017. Vol. 17.. 2. P. 8.

9. Giustina A. et al. Use of pegvisomant in acromegaly. An Italian Society of Endocrinology guideline //Journal of endocrinological investigation. 2014. Vol. 37.. 10. P. 1017-1030.

10. Melmed S. et al. A consensus on the diagnosis and treatment of acromegaly complications //Pituitary. 2013. Vol. 16.. 3. P. 294-302.

11. Standards of Medical Care in Diabetes-2019. Diabetes Care 2019 Jan; 42(Supplement 1): S1-S2

12. Breitschaft A. et al. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study //Diabetes research and clinical practice. 2014. Vol. 103.. 3. P. 458-465